0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editor's Correspondence |

Treatment of MRSA Infections With Older Molecules: A Reasonable Option for Investigation

Houssem Hmouda, MD; Chaker Ben Salem, MD; Kamel Bouraoui, MD; Letaief Jemni, MD
Arch Intern Med. 2007;167(11):1207-1208. doi:10.1001/archinte.167.11.1207-b.
Text Size: A A A
Published online

Extract

In the October 2006 issue of the Archives, Hidayat et al1 addressed an alarming issue related to vancomycin treatment failures for infections caused by vancomycin-susceptible MRSA strains with a relatively high MIC. They suggested the use of combination or alternative therapy for invasive infections.

In fact, the pertinent issue is relevant to alternative therapy. Should we use newer agents or should we go back and reexamine the efficacy of older therapies against MRSA? We might suggest an answer with reference to our clinical findings published 13 years ago by Jemni et al.2 In this series, 26 of 27 patients treated with trimethoprim-sulfamethoxazole for MRSA infections were cured. Newer antistaphylococcal agents certainly have a proven efficacy but are not routinely prescribed. In addition, resistance to quinupristin-dalfopristin and linezolid has emerged.3 Therefore, it is justified to reexamine the clinical efficacy of older therapies active against MRSA. This is particularly interesting because of the recent proliferation of community-acquired MRSA and the consequent marked increase in the need of outpatient treatment of MRSA infections. A recent comparative study on bactericidal activity of orally available agents against MRSA concluded that trimethoprim-sulfamethoxazole is rapidly bactericidal against MRSA in vitro compared with most other orally available antimicrobials.4 Since the early 1970s, the efficacy of trimethoprim-sulfamethoxazole in severe S aureus infections has been reported.5 We believe that the widespread and inappropriate use of vancomycin may have contributed to the emergence of vancomycin-intermediate S aureus and vancomycin-resistant S aureus. The rise in MRSA prevalence will continue to drive not only the increase in empirical use of vancomycin but also aggressive empirical vancomycin dosing. Therefore, returning to older molecules and assessing their clinical efficacy seems to be a reasonable option for investigation.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
brightcove.createExperiences();